Severe Pneumonia Caused by *Streptococcus Pneumoniae* and *Haemophilus Influenzae* Coinfection in an Elderly Patient: A Case Report

Nobuhiro Akuzawa\(^a\), Naoyuki Harada\(^a\), Noriko Hasegawa\(^a\), Hidenori Seki\(^a\), Yuko Oku\(^a\), Masayuki Totsuka\(^a\), Takashi Hatori\(^a\), Jun Murakami\(^a\), Kunihiko Imai\(^a\), Yonosuke Kitahara\(^a\), Masahiko Tashiro\(^a\), Masahiko Kurabayashi\(^b\)

**Abstract**

An 80-year-old man was admitted to our hospital because of worsening dyspnea, fever and sputum. Both chest X-ray film and computed tomography findings showed localized consolidation of the right lower lung. A urine sample was positive for *Streptococcus pneumoniae* antigen. After initial treatment with meropenem for 3 days, his symptoms improved and high-dose ampicillin was substituted for meropenem. However, 3 days later he required intubation for adult respiratory distress syndrome. We reinstituted meropenem therapy and this proved successful. Sputum culture revealed coinfection with penicillin sensitive *S. pneumoniae* and β-lactamase-negative ampicillin-resistant *Haemophilus influenzae*.

**Keywords:** *Streptococcus pneumoniae*; β-lactamase-negative ampicillin-resistant *Haemophilus influenzae*; Adult respiratory distress syndrome

**Introduction**

Even nowadays, community-acquired pneumonia (CAP) continues to be one of the commonest causes of morbidity and mortality worldwide, particularly in the elderly. Epidemiologic studies show that pneumonia ranks fourth among leading causes of death in Japan. *Streptococcus pneumoniae* is an important pathogen in many community-acquired respiratory infections, including CAP, acute bacterial sinusitis, acute otitis media, and in more invasive infections such as meningitis and bacteremia.

The β-Lactam antibiotics have been very effective against *S. pneumoniae*; however, resistance to this class of antibiotic has become an increasing problem. *Haemophilus influenzae* is also a common pathogen in patients with adult CAP and pediatric otitis media and bacterial meningitis. The prevalence of ampicillin resistant strains among *H. influenzae* isolated from the lower respiratory tract of Japanese children has recently increased significantly [1, 2]. *H. influenzae* type b (Hib) is believed to be responsible for serious illness, chiefly meningitis and pneumonia, worldwide. In particular, meningitis remains a serious problem in children in areas where Hib vaccine is not used. In Japan, meropenem plus an expanded-spectrum cephalosporin such as cefotaxime is recommended for treatment of *H. influenzae* meningitis [3].

Here, we describe a patient who we initially diagnosed as having bacterial pneumonia caused by *S. pneumoniae* infection. His illness progressed to adult respiratory distress syndrome a few days after we substituted high-dose ampicillin for meropenem. We found that this progression was due to coinfection with β-lactamase-negative ampicillin-resistant (BLNAR) *H. influenzae*.

**Case Report**

An 80-year-old man was admitted to the emergency ward of our hospital in May 2010 because of dyspnea, brown sputum and chills due to a high fever that he had had for 2 days. He had developed a common cold 1 wk before this admission. He had chronic gastritis and hypertension that was being treated with amlodipine, valsartan and famotidine. He had no history of any respiratory disease and smoking.

On admission, physical examination revealed a high body temperature (39.2 °C) and moist rales in the right lower chest. Shortness of breath was obvious; his blood oxygen saturation (SpO₂) was 92% on room air. Laboratory findings indicated mild inflammation as follows: WBC count, 12,000/mm³; neutrophils, 85.0%; and C-reactive protein...
2.84 mg/dL. His fasting plasma glucose concentration was 160 mg/dL and HbA1c 7.2%, suggesting untreated diabetes mellitus. Other data were normal. We found limited consolidation of the right lower lung on radiographs. Further investigation by computed tomography revealed alveolar infiltration in the right lower lobe and an old dissecting aneurysm of the aortic arch (Fig. 1). However, he had not experienced severe chest pain. Gram stained sputum smear samples revealed a number of Gram-positive diplococci and some phagocytosis. A urine sample was positive for S. pneumoniae antigen. A nasopharyngeal swab was negative for influenza virus type-A and B antigens and his urine was negative for Legionella pneumophila antigen. Based on these findings, we considered that S. pneumoniae was the most likely cause of his bacterial pneumonia. However, we could not exclude the possibility that he was infected with penicillin-intermediate S. pneumoniae (PISP) or penicillin-resistant S. pneumoniae (PRSP). We began intravenous administration of meropenem (1.5 g/day) immediately after hospitalization.

By day 3, his laboratory data had improved: his WBC count was 9,700/mm³ and CRP concentration 3.50 mg/dL. His body temperature was normal and his appetite better. His symptoms of moist cough, headache and general fatigue had also dramatically improved. His partial pressure of O₂ (PaO₂) was 89.3 Torr while inhaling 1 L/min oxygen via a nasal cannula. Because high-dose penicillin can also be effective in the treatment of S. pneumoniae infection, including PISP and PRSP, we reconsidered whether meropenem was the most appropriate antibiotic for him. We consulted our hospital’s Infection Control Team and decided to accept their recommendation to substitute ampicillin (8 g/day) for the meropenem.

He began high-dose ampicillin on day 4. By that evening, his body temperature had increased to 37.8 °C and he was complaining of chills. On the morning of day 5, his SpO₂ suddenly decreased to 87% and his body temperature increased to 39.4 °C. He was experiencing difficulty in breathing in spite of inhaling 10 L/min oxygen via a face mask. Blood gas analysis revealed hypoxemia (PaO₂ 65.3 Torr) and hypocapnia (partial pressure of CO₂ (PaCO₂) 35.2 Torr), indicating he was compensating for respiratory failure by hyperventilating. His WBC count had increased to 12,500/mm³ and his CRP concentration to 15.83 mg/dL. His chest X-ray films had worsened, showing bilateral broad infiltration of the lungs (Fig. 2). An echocardiographic study performed at the patient’s bedside showed a normal left ventricular contraction and relaxation pattern. We therefore concluded that the pulmonary edema was non-cardiogenic and that he had acute adult respiratory distress syndrome due to bacterial pneumonia.

On the same day, penicillin-sensitive S. pneumoniae (PSSP) and BLNAR H. influenzae were detected in the sputum that had been collected at the time of hospital admission. BLNAR H. influenzae was sensitive to cefotaxime, ceftriaxone, clarithromycin, levofloxacin, ciprofloxacin and meropenem. Because PSSP is sensitive to ampicillin, we interpreted these results as indicating that BLNAR H. influenzae had caused the worsening of his pneumonia after the change in his antibiotic regime. We therefore resumed
administration of meropenem (2.0 g/day) and discontinued the high-dose ampicillin therapy.

Although his condition was worse on day 6, we continued to administer meropenem, which is effective against both PSSP and BLNAR H. influenzae infection. He had extreme tachypnea of 40 breaths/min with difficulty in expectoration. His SpO₂ had decreased to 78% on 10 L/min O₂ by face mask. We decided to prescribe sivelestat sodium hydrate, a potent inhibitor of neutrophil-derived elastase and placed him on a ventilator. He required 100% fraction of inspired O₂ (FiO₂) to maintain his SpO₂ above 90%.

His respiratory status began to improve the next day (day 7). His SpO₂ was 95% on 50% FiO₂ and his laboratory data still showed evidence of severe inflammation with WBC count 8,100/mm³ and CRP concentration of 21.77 mg/dL. We consulted the Nutrition Support Team and accepted their recommendation to introduce enteral nutrition with Oxepla (Abbott, Tokyo, Japan), which has been clinically shown to modulate the inflammatory response in critically ill, mechanically ventilated patients, especially those with systemic inflammatory response syndrome, acute lung injury or acute respiratory syndrome. We also asked the physical therapists to institute a rehabilitation program to prevent muscle weakening and contracture, and they immediately began passive exercises.

The patient’s SpO₂ had recovered to 98% on 40% FiO₂ on day 8 and his body temperature had dropped to normal by day 9. His SpO₂ was stable at 100% on 30% FiO₂. We confirmed that he could breathe spontaneously without mechanical ventilation support and successfully withdrew him from artificial respiration on day 10. Fortunately, he showed no neurological deficits from hypoxia-induced brain damage. His clinical course after extubation was excellent. He could take water and liquid food orally by day 12, when we removed his feeding tube. By day 13 his laboratory data had improved dramatically with WBC count 7,800/mm³ and CRP concentration decreased to 0.32 mg/dL. We therefore stopped administering meropenem and he continued rehabilitation for about 3 wks, including leg muscle strengthening exercises. We also prescribed a diabetic diet. We discharged him from our hospital free of any physical problems on day 30.

Discussion

S. pneumoniae has been recognized as the commonest cause of CAP [4, 5]. Miyashita et al reported the incidence of causative pathogens in ambulatory and hospitalized patients with CAP in Japan [6]. According to their report, Mycoplasma pneumoniae is the commonest pathogen found in such outpatients and S. pneumoniae the commonest in hospitalized patients. They drew further distinctions between the pathogens found in outpatients and hospitalized patients with CAP, namely that the incidence of infection with M. pneumoniae is higher among outpatients than among hospitalized patients, whereas the incidence of infection with S. pneumoniae and H. influenzae is higher among hospitalized patients. They concluded that S. pneumoniae and the atypical pathogens, C. pneumoniae and M. pneumoniae, are significant causative micro-organisms in both outpatients and hospitalized patients with CAP in Japan.

The β-Lactam antibiotics are very effective against S. pneumoniae; however, resistance to this class of antibiotics has become an increasing problem. PRSP became widespread in the 1980s [7]. Genetic analysis has revealed that PRSP acquire resistance to penicillin by extensive remodeling of the transpeptidase domain of penicillin-binding protein (PBP) 2B; this reduces their affinity for β-lactams [8]. Therefore, high-dose penicillin is indispensable to the treatment of pneumonia caused by PRSP, and the customary doses of compound antibiotics with β-lactamase inhibitors such as sulbactam/ampicillin and clavulanic acid/amoxicillin may not produce the desired effects. A retrospective study of 306 Japanese patients with pneumonia caused by S. pneumoniae showed that use of β-lactams in the previous 3 months and the presence of chronic obstructive pulmonary disease were associated with penicillin resistance. The failure rate of first
line antibiotics was significantly higher in the resistant group (22.5%) than in the sensitive group (9.0%) [9]. They also reported that penicillin sensitive and resistant organisms were responsible for 177 (57.7%) and 129 (42.3%) cases of pneumonia, respectively.

On the other hand, with \(H.\ influenzae\), resistance to ampicillin and other \(\beta\)-lactam antibiotics is generally limited to either production of a \(\beta\)-lactamase or, in the case of BLNAR strains, the presence of altered PBPs with reduced affinity for \(\beta\)-lactams [10]. A very small proportion of strains possess both mechanisms; these are referred to as \(\beta\)-lactamase-positive amoxicillin-clavulanate-resistant strains [11]. Although \(S.\ pneumoniae\) and \(M.\ pneumoniae\) are the commonest pathogens in adult CAP patients, \(H.\ influenzae\) causes 13% of cases in Japan [6]. The American Thoracic Society and the Infectious Disease Society of America have established treatment guidelines for management of CAP in immunocompetent adults [12, 13]. Recommendations for inpatients in medical wards include levofloxacin, gatifloxacin, enrofloxacin, gemifloxacin, or moxifloxacin alone or azithromycin or clarithromycin plus ceftriaxone, ampicillin-sulbactam, and etepenem.

In Japan, the Japanese Respiratory Society (JRS) has provided guidelines for the management of CAP in adults, including an update and new recommendations in 2006 [14]. To assess CAP severity, the guideline committee advocates a simplified scoring system based on characteristics in Japan and including the following five variables: age (men \( \geq \) 70 yr, women \( \geq \) 75 yr); blood urea nitrogen \( \geq \) 21 mg/dL or presence of dehydration; \(\text{SpO}_2 \leq 90\%\) (\(\text{PaO}_2 \leq 60\) Torr); impaired consciousness (confusion); and low blood pressure (systolic blood pressure \( \leq \) 90 mmHg). The number of positive items reflects the severity of the pneumonia, which influences the patient’s prognosis. Thus, they recommend that patients with scores of \( \geq \) 3 receive treatment in hospital. The Japanese CAP guidelines also emphasize the importance of using rapid diagnostic tests to differentiate between atypical and bacterial pneumonia to allow selection of an appropriate antibiotic. In the present case, our patient’s score was 1 (age: 80 yr old) and the results of both a Gram stain of sputum and the urine pneumococcal rapid antigen test suggested bacterial pneumonia, specifically pneumonia caused by \(S.\ pneumoniae\). According to the guidelines, either treatment at home with oral medication or in hospital with intravenous antibiotics is appropriate. However, sudden unpredictable deterioration due to florishing of BLNAR \(H.\ influenzae\) occurred after substitution of ampicillin for меропenem. High dose ampicillin did not prevent this patient from deteriorating because of strong resistance of BLNAR \(H.\ influenzae\) to ampicillin. It is noteworthy that the BLNAR \(H.\ influenzae\) isolated from this patient was sensitive to macrolides and fluoroquinolones. Combined macrolide-\(\beta\)-lactam or fluoroquinolone-\(\beta\)-lactam therapy might have altered the clinical course of the present case.

We also provided this patient with nutritional support. Initially, we started enteral feeding with Oxepa (Abott), a unique product that contains eicosapentanoic (EPA) and gamma-linolenic acids (GLA). Acute respiratory distress syndrome patients fed an enteral diet containing EPA and GLA and large amounts of various antioxidants (Oxepa) have significantly reduced pulmonary inflammation, increased oxygenation, and improved clinical outcomes than patients not fed this product [15]. Feeding of acute respiratory distress syndrome patients with Oxepa results not only in a reduction in neutrophils in bronchoalveolar lavage fluid (BALF) and in alveolar membrane protein permeability, but also in a decrease in amounts of interleukin-8 and leukotriene B4 in BALF [16]. Thus, early feeding with Oxepa may have contributed to the clinical improvement of this patient.

In conclusion, we here describe a rare case of an elderly patient with severe bacterial pneumonia, initially due to \(S.\ pneumoniae\), that developed into coinfection with BLNAR \(H.\ influenzae\). Although we conformed to the guidelines provided by the JRS for the management of CAP in adults, we were unable to prevent worsening of this patient’s bacterial pneumonia. Prudent decisions are necessary when choosing the initial antibiotics for CAP patients.

**Acknowledgement**

This work was done at Social Insurance Gunma Chuo General Hospital, Maebashi, Gunma, Japan.

**Conflict of Interest**

No conflict of interest.

**Grant Support**

No funding.

**References**

3. Hasegawa K, Kobayashi R, Takada E, Ono A, Chiba N, Morozumi M, Iwata S, et al. High prevalence of type b pneumonia, resistance to ampicillin and other \(\beta\)-lactam antibiotics is generally limited to either production of a \(\beta\)-lactamase or, in the case of BLNAR strains, the presence of altered PBPs with reduced affinity for \(\beta\)-lactams [10]. A very small proportion of strains possess both mechanisms; these are referred to as \(\beta\)-lactamase-positive amoxicillin-clavulanate-resistant strains [11]. Although \(S.\ pneumoniae\) and \(M.\ pneumoniae\) are the commonest pathogens in adult CAP patients, \(H.\ influenzae\) causes 13% of cases in Japan [6]. The American Thoracic Society and the Infectious Disease Society of America have established treatment guidelines for management of CAP in immunocompetent adults [12, 13]. Recommendations for inpatients in medical wards include levofloxacin, gatifloxacin, enrofloxacin, gemifloxacin, or moxifloxacin alone or azithromycin or clarithromycin plus ceftriaxone, ampicillin-sulbactam, and etepenem.

In Japan, the Japanese Respiratory Society (JRS) has provided guidelines for the management of CAP in adults, including an update and new recommendations in 2006 [14]. To assess CAP severity, the guideline committee advocates a simplified scoring system based on characteristics in Japan and including the following five variables: age (men \( \geq \) 70 yr, women \( \geq \) 75 yr); blood urea nitrogen \( \geq \) 21 mg/dL or presence of dehydration; \(\text{SpO}_2 \leq 90\%\) (\(\text{PaO}_2 \leq 60\) Torr); impaired consciousness (confusion); and low blood pressure (systolic blood pressure \( \leq \) 90 mmHg). The number of positive items reflects the severity of the pneumonia, which influences the patient’s prognosis. Thus, they recommend that patients with scores of \( \geq \) 3 receive treatment in hospital. The Japanese CAP guidelines also emphasize the importance of using rapid diagnostic tests to differentiate between atypical and bacterial pneumonia to allow selection of an appropriate antibiotic. In the present case, our patient’s score was 1 (age: 80 yr old) and the results of both a Gram stain of sputum and the urine pneumococcal rapid antigen test suggested bacterial pneumonia, specifically pneumonia caused by \(S.\ pneumoniae\). According to the guidelines, either treatment at home with oral medication or in hospital with intravenous antibiotics is appropriate. However, sudden unpredictable deterioration due to florishing of BLNAR \(H.\ influenzae\) occurred after substitution of ampicillin for меропenem. High dose ampicillin did not prevent this patient from deteriorating because of strong resistance of BLNAR \(H.\ influenzae\) to ampicillin. It is noteworthy that the BLNAR \(H.\ influenzae\) isolated from this patient was sensitive to macrolides and fluoroquinolones. Combined macrolide-\(\beta\)-lactam or fluoroquinolone-\(\beta\)-lactam therapy might have altered the clinical course of the present case.

We also provided this patient with nutritional support. Initially, we started enteral feeding with Oxepa (Abott), a unique product that contains eicosapentanoic (EPA) and gamma-linolenic acids (GLA). Acute respiratory distress syndrome patients fed an enteral diet containing EPA and GLA and large amounts of various antioxidants (Oxepa) have significantly reduced pulmonary inflammation, increased oxygenation, and improved clinical outcomes than patients not fed this product [15]. Feeding of acute respiratory distress syndrome patients with Oxepa results not only in a reduction in neutrophils in bronchoalveolar lavage fluid (BALF) and in alveolar membrane protein permeability, but also in a decrease in amounts of interleukin-8 and leukotriene B4 in BALF [16]. Thus, early feeding with Oxepa may have contributed to the clinical improvement of this patient.

In conclusion, we here describe a rare case of an elderly patient with severe bacterial pneumonia, initially due to \(S.\ pneumoniae\), that developed into coinfection with BLNAR \(H.\ influenzae\). Although we conformed to the guidelines provided by the JRS for the management of CAP in adults, we were unable to prevent worsening of this patient’s bacterial pneumonia. Prudent decisions are necessary when choosing the initial antibiotics for CAP patients.

**Acknowledgement**

This work was done at Social Insurance Gunma Chuo General Hospital, Maebashi, Gunma, Japan.

**Conflict of Interest**

No conflict of interest.

**Grant Support**

No funding.

**References**


